IL287394A - In the s4 crystal form of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-(cis-2,6-dimethylmorpholino)methyl)styrol)- 1 h-imidazol-6-yl)-5' -Methoxyspirio[cyclopropane-1,3'-indoline]-2'-one fumarate - Google Patents

In the s4 crystal form of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-(cis-2,6-dimethylmorpholino)methyl)styrol)- 1 h-imidazol-6-yl)-5' -Methoxyspirio[cyclopropane-1,3'-indoline]-2'-one fumarate

Info

Publication number
IL287394A
IL287394A IL287394A IL28739421A IL287394A IL 287394 A IL287394 A IL 287394A IL 287394 A IL287394 A IL 287394A IL 28739421 A IL28739421 A IL 28739421A IL 287394 A IL287394 A IL 287394A
Authority
IL
Israel
Prior art keywords
methoxyspiro
dimethylmorpholino
indolin
cyclopropane
styryl
Prior art date
Application number
IL287394A
Other languages
English (en)
Hebrew (he)
Inventor
Sze-Wan Li
Mark Robert Bray
Original Assignee
Univ Health Network
Li Sze Wan
Mark Robert Bray
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network, Li Sze Wan, Mark Robert Bray filed Critical Univ Health Network
Publication of IL287394A publication Critical patent/IL287394A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL287394A 2019-04-24 2021-10-19 In the s4 crystal form of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-(cis-2,6-dimethylmorpholino)methyl)styrol)- 1 h-imidazol-6-yl)-5' -Methoxyspirio[cyclopropane-1,3'-indoline]-2'-one fumarate IL287394A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24
PCT/CA2020/050535 WO2020215155A1 (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Publications (1)

Publication Number Publication Date
IL287394A true IL287394A (en) 2021-12-01

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287394A IL287394A (en) 2019-04-24 2021-10-19 In the s4 crystal form of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-(cis-2,6-dimethylmorpholino)methyl)styrol)- 1 h-imidazol-6-yl)-5' -Methoxyspirio[cyclopropane-1,3'-indoline]-2'-one fumarate

Country Status (15)

Country Link
US (1) US12325700B2 (enExample)
EP (1) EP3959209A4 (enExample)
JP (1) JP7705351B2 (enExample)
KR (1) KR20220004102A (enExample)
CN (1) CN113966330B (enExample)
BR (1) BR112021021106A2 (enExample)
CA (1) CA3137191A1 (enExample)
EA (1) EA202192903A1 (enExample)
IL (1) IL287394A (enExample)
MA (1) MA55767A (enExample)
MX (1) MX2021012993A (enExample)
SA (1) SA521430647B1 (enExample)
SG (1) SG11202111003UA (enExample)
TW (1) TWI862582B (enExample)
WO (1) WO2020215155A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013225A (es) 2021-05-11 2024-01-15 Oric Pharmaceuticals Inc Inhibidores de la cinasa 4 similar a polo.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
JP2011506494A (ja) 2007-12-21 2011-03-03 ユニバーシティ・ヘルス・ネットワーク 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
PT2556071T (pt) 2010-04-06 2016-11-22 Univ Health Network Inibidores de quinase e seus usos no tratamento de cancro
WO2012000103A1 (en) 2010-07-02 2012-01-05 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
KR20130105675A (ko) 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
ES2908200T3 (es) 2013-10-18 2022-04-28 Univ Health Network Tratamiento para el cáncer de páncreas
HRP20190564T1 (hr) 2013-10-18 2019-05-17 University Health Network Sol i kristalni oblici inhibitora plk-4

Also Published As

Publication number Publication date
KR20220004102A (ko) 2022-01-11
TWI862582B (zh) 2024-11-21
JP2022530028A (ja) 2022-06-27
BR112021021106A2 (pt) 2021-12-14
MA55767A (fr) 2022-03-02
MX2021012993A (es) 2021-12-10
JP7705351B2 (ja) 2025-07-09
CN113966330B (zh) 2024-09-13
WO2020215155A8 (en) 2020-11-26
CN113966330A (zh) 2022-01-21
US20220204494A1 (en) 2022-06-30
US12325700B2 (en) 2025-06-10
CA3137191A1 (en) 2020-10-29
WO2020215155A1 (en) 2020-10-29
EA202192903A1 (ru) 2022-02-09
SA521430647B1 (ar) 2024-01-27
EP3959209A4 (en) 2022-12-28
EP3959209A1 (en) 2022-03-02
TW202104216A (zh) 2021-02-01
SG11202111003UA (en) 2021-11-29
AU2020264143A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
DK2080516T3 (da) Anvendelse af isothiocyanatderivater som anti-myelom-midler
EP4028094A4 (en) Patient interface and positioning and stabilising structure for the patient interface
IL292263A (en) Alternative compounds 4-aminoisoindoline-1,3 dione and second active substances for combined use
EP3927729A4 (en) Therapeutic antibody formulation
EP3481428A4 (en) ADHESIVE ORAL SOLDERED FOILS FOR CARING THE MOUTH CARE
EP3844096A4 (en) FOLLOWER PLATE GEOMETRY
EP4073701A4 (en) Integrated dose counter
EP3816330A4 (en) CRYSTALLINE OXIDE FILM
EP4054548A4 (en) Adhesive compositions comprising therapeutics
EP3959209A4 (en) S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE
EP3999529A4 (en) HEMOGLOBIN-BASED THERAPEUTIC AGENT
HK40070200A (en) Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate
EP3302466A4 (en) 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases
NO20023111L (no) Utvortes preparat for behandling av pruritus
EP3953677A4 (en) TISSUE EMBEDDED CASSETTE WITH SHIELDING
AU2019904269A0 (en) Implants for the Prolonged Release of Active Agents
EP3681487A4 (en) SELF-ADHESIVE FILM FOR DISPENSING ACTIVE INGREDIENTS
HK40046683A (en) Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
SG10202006305VA (en) FOD adhesive film and semiconductor package including the same
HK40072482A (en) Compounds for the treatment of kinase-dependent disorders
HK40078208A (en) Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
HK40077316A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
HK40072172A (en) Ophthalmic composition devoid of chelators for use in a method for the treatment of an ocular disorder